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Abstract
Purpose—Numerous studies establish associations between adverse perinatal outcomes/
complications and autism spectrum disorder (ASD). There has been little assessment of population 
attributable fractions (PAFs).
Methods—We estimated average ASD PAFs for preterm birth (PTB), small for gestational age 
(SGA), and Cesarean delivery (CD) in a U.S. population. Average PAF methodology accounts for 
risk factor co-occurrence. ASD cases were singleton non-Hispanic white, non-Hispanic black, and 
Hispanic children born in 1994 (n = 703) or 2000 (n = 1339) who resided in 48 U.S. counties 
included within eight Autism and Developmental Disabilities Monitoring Network sites. Cases 
were matched on birth year, sex, and maternal county of residence, race-ethnicity, age, and 
education to 20 controls from U.S. natality files. Results: For the 1994 cohort, average PAFs were 
4.2%, 0.9%, and 7.9% for PTB, SGA, and CD, respectively. The summary PAF was 13.0% 
(1.7%–19.5%). For the 2000 cohort, average PAFs were 2.0%, 3.1%, and 6.7% for PTB, SGA, 
and CD, respectively, with a summary PAF of 11.8% (7.5%–15.9%).
Conclusions—Three perinatal risk factors notably contribute to ASD risk in a U.S. population. 
Because each factor represents multiple etiologic pathways, PAF estimates are best interpreted as 
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the proportion of ASD attributable to having a suboptimal perinatal environment resulting in PTB, 
SGA, and/or CD.
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Introduction
Autism spectrum disorders (ASDs) are characterized by social and communication 
impairments and restricted, stereotyped patterns of behavior [1]. ASD prevalence in the U.S. 
[2–4] and other populations [5–9] has increased markedly and is currently estimated at 1%–
2% [2–9]. Numerous genetic factors are implicated in the etiology of ASDs [10] and twin 
studies suggest high heritability [11]; the composite evidence supports gene-environment 
interactions. Research on nongenetic risk factors is evolving. Numerous studies document 
associations between ASD and various adverse perinatal outcomes and complications [12]. 
Limited studies suggest associations between ASD and more specific maternal exposures 
such as infections [13,14], medications [15–17], and environmental pollutants [18,19].
For most ASD risk factors, there has been no assessment of population attributable fractions 
(PAFs). We estimated PAFs for three perinatal risk factors, preterm birth (PTB), small for 
gestational age (SGA), and Cesarean delivery (CD) among U.S. children included in the 
Autism and Developmental Disabilities Monitoring (ADDM) Network and compared PAFs 
from the most recent ADDM surveillance year with those from an earlier time. We chose 
factors that were both relatively common (≥10% population prevalence) and thus could 
substantively contribute to the population ASD burden and established as ASD risk factors 
through multiple studies in a range of populations [12]. Nonetheless, each factor represents a 
composite of multiple potential underlying etiologic mechanisms. Their PAF estimates are 
thus best interpreted as the proportion of ASD attributable to having a suboptimal perinatal 
environment resulting in PTB, SGA, and/or CD.
Methods
Study population
The ADDM Network is an ongoing ASD surveillance program among 8-year-old children 
residing in selected U.S. population–based sites. Thirteen sites participated in the 2002 
ADDM surveillance year and 14 participated in the 2008 surveillance year.
For children meeting birth year and residence eligibility criteria, each ADDM site reviews 
special education records and medical records from providers who conduct developmental 
evaluations. Records with documentation of an ASD diagnosis or education classification or 
behavioral characteristics consistent with possible ASD are fully abstracted. Data abstracted 
include demographics, ASD and other disability diagnoses, behavioral descriptions from 
developmental evaluations, and intelligence quotient (IQ) score. Abstractions from different 
sources for the same child are concatenated. Trained clinicians review the composite 
abstractions using a standardized protocol based on the Diagnostic and Statistical Manual of 
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Mental Disorders (Fourth Edition Text Revision) to classify children as having or not 
having ASDs [1]. Sites link their final data for ASD cases to state natality files; across sites 
70% of children are born in-state and match a birth record.
Study population, cases
Our sample selection strategy is outlined in the Appendix. We initially selected children 
classified as ASD cases in 2002 or 2008 from 13 sites that participated in ADDM both 
years. Because ADDM tracks children aged 8 years, these children were born in 1994 and 
2000. We further selected children residing both at birth and during the surveillance year in 
counties included in ADDM sites' catchment areas in both 2002 and 2008. This narrowed 
our population, as the geographic boundaries changed for some sites. In addition, the birth 
residence restriction (which was necessary to ensure comparability with controls) meant that 
we pragmatically restricted our population to sites that included the maternal residence 
county indicator in their submitted ADDM-natality data set (three sites did not) and to 
children linked to their birth record. We further excluded two sites that did not provide other 
needed variables. These selection criteria, although not impacting internal validity, did 
narrow the generalizability. Nonetheless, our defined study population still included 48 
counties from eight states. Because of subgroup sample size constraints, we further limited 
the population to singleton non-Hispanic white (NHW), non-Hispanic black (NHB), and 
Hispanic children (n = 747 and 1406 cases from 2002 and 2008, respectively).
During analysis, we excluded a small percentage of children (3% from 2002 and 1% from 
2008) missing data on one or more study variables and a small percentage of children (3% 
from both 2002 and 2008) included in a final matching stratum with a low number of 
potential controls per case (see the following section). Our final analytic sample included 
703 children from 2002 ADDM (1994 birth cohort) and 1339 children from 2008 ADDM 
(2000 cohort).
Study population, controls
Although sites link their ADDM and natality datafiles, the deidentified data they submit for 
the pooled data set include only ASD cases (i.e., unlinked births from sites' natality files are 
not provided). Thus, we selected controls from public-use 1994 and 2000 U.S. natality files. 
We could not discern which births within those files were subsequently identified as ADDM 
cases (and thus, already included in our sample). Given the relatively low ASD population 
prevalence, the overall probability of selecting a case as a control was low.
To carefully and efficiently consider confounders, we used a matched design. We matched 
each case to 20 controls from the same birth year on sex, maternal race-ethnicity (NHW, 
NHB, Hispanic), county of residence, age (<20, 20–29, 30–34, 35+ years), and education 
(high school or less, greater than high school) at birth. We selected a high number of 
controls because the PAF methodology combined with modeling methods used resulted in a 
loss of controls within certain strata.
Public-use natality files do not include the specific maternal residence county for county 
populations less than 100,000. Rather, a general “small-county” indicator is provided. Thus, 
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cases with a maternal county population of 100,000 or higher were exactly matched to 
controls on maternal residence county, whereas cases born to mothers from small-population 
counties were matched on the general small-county indicator for the state.
Given both number and type of matching factors, our sample was subdivided into numerous 
matching strata, some with a small number of births. Thus, one study selection criterion was 
birth within a study-matching stratum including a minimum of 20 potential controls.
Even still, some included strata were small and there was a nonnegligible possibility that we 
inadvertently selected the case as one of the controls. We conducted sensitivity analyses to 
assess the impact of this possible problem (see the following section).
Perinatal factors
PTB, SGA, and CD were derived from natality file data. PTB was defined as gestational age 
less than 37 completed weeks. Gestational age was based on last menstrual period or clinical 
estimate when last menstrual period was missing. SGA was defined as birth weight for 
gestational age less than 10th percentile of sex-specific referent curves for U.S. singleton 
livebirths between 1999 and 2000 [20]. CD included both primary and secondary CD.
Statistical methods
We estimated the summary PAF of exposure to any one of the three risk factors (PTB, SGA, 
or CD), alone or in any combination with any of the other factors. This represents the 
maximum proportion of ASD cases attributable to this risk factor set. Then, we partitioned 
the summary PAF into unique average PAFs for each risk factor to estimate proportions of 
ASD cases attributable to each factor on average, while considering the interaction among 
factors and the dynamic nature of the risk factors in the population. Average PAFs account 
for co-occurrence among the three factors while adjusting for other potential confounders; 
thus, in general, average PAFs address the inherent over-estimation that occurs when 
computing separate crude or adjusted PAFs [21].
The average PAF is a summary estimate that considers all possible sequences of eliminating 
risk factors in a defined risk factor set. This methodology requires estimation of multiple 
sequential PAFs. For example, one sequence for this analysis addresses the hypothetical 
question, what would be the impact on ASD prevalence if one could first eliminate PTB 
from the population, followed by SGA, followed by CD. One sequential PAF is estimated 
for each factor in this sequence and an average PAF for each risk factor is derived using the 
simple average of all sequential PAFs for that factor.
Calculation of average PAFs for our defined risk factor set required 18 stratum-specific odds 
ratios (ORs) (six/factor) and a summary OR for the association with any one or more of the 
factors. Strata were defined based on the presence or absence of the perinatal factor(s) in the 
risk factor set that were not being assessed in a given calculation. Summary PAFs, then 
sequential and average PAFs, were derived using the stratum-specific ORs and 
corresponding proportions of exposed cases [22,23].
Schieve et al. Page 4
Ann Epidemiol. Author manuscript; available in PMC 2015 September 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Given the matched design, we used conditional logistic regression to calculate ORs adjusted 
for the matching factors. In sequential PAF calculations, not all cases and controls in a 
matched analysis are informative because some controls matched to a case on demographic 
factors are not included in the same perinatal risk factor strata as the case. Our selection of 
20 controls per case helped stabilize stratum-specific estimations.
In addition, we re-estimated ORs using an unmatched methodology, unconditional logistic 
regression, in which none of the cases or controls dropped out of the models. We included 
four of the five matching factors as independent variables: child sex, maternal race-ethnicity, 
age, and education. However, we could not adjust for maternal residence county because of 
the large number of distinct counties in our population. The findings from conditional and 
unconditional logistic regression were very similar; thus, we only present the former.
We also performed sensitivity analyses to consider the potential problem that in some case-
control sets, one selected control was actually the case. For 25% of 1994 birth cohort cases 
and 31% of 2000 cohort cases, one of the 20 controls had exact or nearly exact (one minor 
discrepancy only) values for seven birth variables (exact birth weight, exact gestational age, 
exact maternal and paternal ages, years of education, marital status, and parity). We re-
estimated PAFs after excluding these questionable controls. All re-estimates matched our 
original findings within one-tenth of a percent.
We analyzed the 1994 and 2000 birth cohorts separately and calculated summary PAFs for 
subgroups based on sex and co-occurring intellectual disability (ID, defined as IQ score 
<70).
We estimated 95% confidence limits (CLs) for average and summary PAFs using a 
bootstrap technique with 1000 replicates. Each resampled data set comprised case-control 
sets from the original study sample randomly selected with replacement. CLs were estimated 
as the 2.5 and 97.5 percentiles of the 1000 replica estimates. Small sample sizes precluded 
CL estimation for average PAFs among the 1994 birth cohort. We thus developed a hybrid 
method, in which we applied information gleaned from the 2000 cohort to the 1994 cohort. 
For the 2000 cohort, we compared variance estimates based on the bootstrap methodology to 
those based on a simplistic calculation that assumed all covariances were 0 (the most naïve 
assumption). We assumed that relative differences between bootstrap and naive variance 
estimates were similar for the two cohorts and thus applied the 2000 cohort variance ratio 
(bootstrap/naive) to naive variance estimates for the 1994 cohort.
Naive variance estimates were generated in the Interactive Risk Assessment Program 
version 2.2 (U.S. National Cancer Institute, Bethesda, MD) [24,25]. All other analyses were 
performed using SAS version 9.2 (SAS Institute Inc., Cary, NC) [26,27].
Human subjects review was not required for this secondary analysis of de-identified data.
Results
The majority of ASD cases from both birth cohorts were male, NHW, and were from three 
sites: Arizona, Georgia, and Missouri (Table 1). For more than 40%, maternal age at birth 
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was 30 years or older and for more than 50%, maternal education was greater than high 
school.
Overall, the frequencies of PTB, SGA, and CD among cases were 13%–14%, 11%–12%, 
and 27%–28%, respectively, for both cohorts (Table 2). The proportion of cases with any of 
the three was 44% for both cohorts. The proportion of cases with all three factors was 0.7% 
and 1.0%, for the 1994 and 2000 cohorts, respectively. For both cohorts, the percentages of 
the risk factors, overall, and in various strata of the other factors was lower among the 
controls than cases, with only one exception (SGA without PTB or CD in the 1994 cohort).
Adjusted (matched) ORs for each risk factor indicated modest associations with ASD (Table 
3). Moreover, within both cohorts, nearly all the 18 stratum-specific ORs were greater than 
1.0 (although some CLs included 1.0), indicating that children with ASD were more likely 
to have each risk factor alone or together with other risk factors. The summary OR for 
having at least one of the factors was 1.4 for both cohorts.
For the 1994 cohort, average PAFs for PTB, SGA, and CD were 4.2%, 0.9%, and 7.9% 
respectively, with a summary PAF of 13.0% (7.7%–19.5%) (Table 4 and Fig. 1). For the 
2000 cohort, average PAFs for PTB, SGA, and CD were 2.0%, 3.1%, and 6.7%, 
respectively, with a summary PAF of 11.8% (7.5%–15.9%). The slight difference in 
summary PAFs between cohorts was not statistically significant. Subgroup analyses for both 
cohorts (Table 4) were suggestive of a slightly higher summary PAF for ASD cases with co-
occurring ID; however, CLs for the two subgroups with and without ID overlapped and the 
large PAF difference for the subgroup with ID unknown is difficult to interpret. The findings 
for males versus females were imprecise and inconsistent.
Discussion
The trend of increasing prevalence of diagnosed/identified ASDs has not yet abated [2–4]. 
We recently developed a mathematical model to quantify possible contributions of given 
risk factors to the trend and assessed several factors in depth including PTB, SGA, and CD 
[12]. We demonstrated that none contributed substantively to the recent ASD prevalence 
increases. Nonetheless, relative associations between ASD and each factor are well 
documented [12]. Thus, these factors might still contribute to the population prevalence of 
ASD at a point in time. In addition, the individual PAFs for ASD risk factors might change 
over time (if the magnitude of the risk factor-ASD association or proportion of exposed 
cases changes).
We found that 12%–13% of ASDs among children born in 1994 and 2000 in the 48 U.S. 
counties represented in this analysis were attributable to the underlying pathways leading to 
PTB, SGA, and/or CD. There was no change over time in this summary PAF. Nonetheless, 
individual PAFs fluctuated slightly. Both the ORs and proportion of cases “exposed” to 
SGA overall and alone (i.e., without either PTB or CD) increased between 1994 and 2000, 
resulting in an increase in average PAF. Conversely, the ORs and proportion of cases 
exposed to CD decreased slightly resulting in a slight decrease in average PAF. Finally, 
although ORs for PTB did not change over time, the proportion exposed to PTB alone 
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decreased notably, which again resulted in a decrease in average PAF. The increase in the 
PAF for SGA offset the declines in PAFs for CD and PTB. Thus, the summary PAF, which 
more globally represents suboptimal perinatal environment, remained stable.
This study has several strengths including use of data from a well-defined consistent 
population at two time points, use of a matched design to efficiently consider potential 
confounders, and use of a rigorous PAF estimation methodology that addressed inherent 
biases present in most PAF studies. By calculating average PAFs that considered three 
factors as a risk factor set, rather than separately calculating adjusted PAFs, we accounted 
for the known co-occurrence between perinatal factors.
Several study limitations should also be considered. Average PAF estimation methodology 
becomes computationally intensive for assessment of more than three risk factors. We 
examined three prevalent but heterogeneous perinatal risk factors, each with multiple 
potential underlying pathways. For example, it is unknown whether the PTB-ASD 
association is directly causal or represents another mechanism such as maternal infection or 
inflammation. Likewise, the PAF for CD represents a composite of all reasons for having a 
CD along with any direct effects. Thus, although the findings are informative on a 
population level, they do not indicate which etiologic subgroups of PTB, SGA, and CD most 
contribute to ASD. This is perhaps particularly important with regard to CD, as these study 
findings point to risk contributions from a suboptimal perinatal environment generally but 
are not sufficiently detailed to make recommendations about any specific clinical practices. 
Currently, none of the available software for calculating average PAFs includes variance 
estimation when confounder adjustment is taken into account. Thus, we developed a general 
CL estimation method based on a bootstrap sampling technique. In addition to being 
computationally complex, we encountered sample size constraints, necessitating the 
development of a hybrid method for some estimations. Nonetheless, to our knowledge, this 
is the first study to report the precision of average PAF estimates. Finally, generalizability 
should be considered, given our study population was limited to NHW, NHB, and Hispanic 
children born in singleton deliveries in 48 U.S. counties from eight states.
For most sites included in our study population, the ASD prevalence was near the ADDM 
average; however, some sites with lower-and higher-than-average prevalence estimates were 
also included [2]. Our study populations for both cohorts were comparable with the total 
ADDM populations on sex and maternal age (data not shown). The 2000 birth cohort was 
also comparable on race-ethnicity and maternal education, although proportions of His-
panics and advanced maternal education were slightly lower for the 1994 cohort study 
population. For both cohorts, our study populations had slightly lower preterm and SGA 
rates and slightly higher CD rates than the total ADDM populations. The risk factor-ASD 
matched ORs reported here (1.1–1.5, for each perinatal factor overall) are in line with 
previous studies, albeit toward the more conservative end of the range of estimates we 
recently reported from a systematic literature review [12]. Thus, PAFs for other U.S. 
populations might vary slightly from those reported here. Because we noted variability in 
risk factor prevalences across the eight included sites, we conducted sensitivity analyses in 
which we recalculated PAFs after removing each site's data; none of these findings were 
substantively different from the original (data not shown).
Schieve et al. Page 7
Ann Epidemiol. Author manuscript; available in PMC 2015 September 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
This study establishes that perinatal risk factors (or suboptimal perinatal environment) make 
a notable contribution to ASD risk in a U.S. population. However, a large proportion (87%) 
of the ASD burden was not attributed to the three factors we examined. Further study is 
needed to investigate PAFs in other populations, for other risk factors, and in the context of 
gene-environment interactions. The summary and average PAFs reported here represent the 
impact of this risk factor set on the population burden of ASD. Complete prevention of these 
risk factors in the population would be necessary to reduce the ASD prevalence by the 
proportion suggested by the PAFs. Given that complete elimination of PTB, SGA, and CD is 
improbable, potential impact fractions could be estimated in future research assessing the 
relative efficacy of interventions for PTB, SGA, and CD.
Appendix. Sample selection steps by birth cohort
Selection criteria 1994 Birth cohort (ascertained as having 
ASD in 2002 ADDM)
2000 Birth cohort (ascertained as having 
ASD in 2008 ADDM)
No. of sites No. of counties No. of cases No. of sites No. of counties No. of cases
Selection of final study population (population to which results can be generalized)
 ADDM sites 
included in both 2002 
and 2008 surveillance 
years
13 175 2529 13 98 3609
 Limit to: counties 
included in both 2002 
and 2008*
13 94 1825 13 94 3285
 Limit to: children 
residing in same 
county at birth and 
age 8†
10 69 951 10 69 1880
 Limit to: ADDM 
site that provided all 
necessary study 
variables
8 48 786 8 48 1551
 Limit to: singletons 8 48 762 8 48 1489
 Limit to: race-
ethnicity NHW, 
NHB, Hispanic
8‡ 48 747 8 48 1406
Sample exclusions
 Children excluded 
if they lacked data on 
any study variable
726 1386
 Children in 
matching stratum 
with <20 controls/
case excluded§
703 1339
*Not all ADDM sites included the same counties in their surveillance area in 2002 and 2008.
†
In addition to limiting to children identified as ASD cases in ADDM who were linked to a birth record indicating birth 
residence was within the ADDM catchment area, this restriction also pragmatically limited our sample to ADDM sites that 
included the maternal county of residence indicator in their submitted ADDM-natality data set; three sites did not.
‡
Final study population included NHW, NHB, and Hispanic children born as singletons in 48 counties within eight ADDM 
sites.
§
Twenty controls per case were selected using a matched design in which cases and controls were matched on five 
sociodemographic factors. Thus, for control selection, the study population was subdivided into numerous matching strata 
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and some included a small number of births. The final sample selection criterion was birth within a study-matching stratum 
including a minimum of 20 potential controls.
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Fig. 1. 
Average and summary ASD PAFs for PTB, SGA, and CD for the 1994 birth cohort (part A) 
and 2000 birth cohort (part B).
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Table 1
Characteristics of study cases, 1994 versus 2000 birth cohorts
Characteristic 1994 Birth cohort 2000 Birth cohort
% Distribution % Distribution
Study site
 Alabama 12.2 9.8
 Arizona 18.8 20.7
 Arkansas 4.1 2.5
 Georgia 23.5 24.4
 Maryland 9.5 9.6
 Missouri 19.9 19.0
 North Carolina 10.4 12.0
 Utah 1.6 2.0
Child sex
 Male 82.5 83.4
 Female 17.5 16.7
Maternal race-ethnicity
 Non-Hispanic white 69.7 68.6
 Non-Hispanic black 25.8 24.1
 Hispanic 4.6 7.3
Maternal age at birth, y
 <20 7.3 7.0
 20–29 48.2 45.6
 30–34, 28.6 28.6
 35+ 15.9 18.9
Maternal education at birth
 High school or less 42.4 38.2
 Greater than high school 57.6 61.8
Ann Epidemiol. Author manuscript; available in PMC 2015 September 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Schieve et al. Page 13
Table 2
Prevalence of perinatal risk factors, overall and in various combinations, for study cases 
and controls
Risk factor(s) 1994 Birth cohort 2000 Birth cohort
Cases % Controls % Cases % Controls %
PTB (overall) 13.5 10.7 13.1 10.6
SGA (overall) 11.2 10.3 12.0 9.3
CD (overall) 27.5 20.8 28.3 22.7
PTB or SGA or CD 44.2 36.1 44.0 36.7
PTB only 9.3 7.2 7.4 6.9
SGA only 6.4 7.3 7.5 6.4
CD only 21.3 16.3 20.6 17.9
PTB + SGA 1.1 0.7 0.8 0.6
PTB + CD 2.4 2.4 4.0 2.6
SGA + CD 3.0 1.7 2.8 1.7
PTB + SGA + CD 0.7 0.5 1.0 0.5
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